Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of the ...

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ...

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno ...